Welcome and Introduction
Cardiometabolic Comorbidities in Psoriasis: Bridging the Evidence to Practice Gap
Álvaro González-Cantero, MD, PhD, Spain
Global Healthcare Study on Psoriasis: Achievements and Perspectives
Julia-Tatjana Maul, MD, Switzerland
Psoriasis and Tuberculosis in the Era of New Biologic Therapies
Tiago Torres, MD, PhD, Portugal
Small Molecules in Psoriasis: Do Big Things Come in Small Packages?
Lluís Puig, MD, PhD, Spain
Psoriasis and Sexual Impairment
Anna López Ferrer, MD, PhD, Spain
The Psoriasis – Atopic Dermatitis Spectrum: Overlapping Forms: The Next Frontier
José Manuel Carrascosa, MD, PhD, Spain
Q & A and Closing Comments
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
